Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257406 | 0.88 | ACHE (0.52) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| Ammonia Solution, Strong SCHEMBL28824259 | 0.86 | ACHE (0.50) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL8441511 | 0.80 | ACHE (0.44) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL10797679 | 0.80 | ACHE (0.55) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL5490186 | 0.80 | ACHE (0.55) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL931982 | 0.80 | ACHE (0.55) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL29352930 | 0.80 | ACHE (0.55) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL99347 | 0.80 | ACHE (0.55) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL29378635 | 0.80 | ACHE (0.55) | ACHEACP3ALDH1A1MAPK1AOC3 | |
| SCHEMBL23183184 | 0.79 | ACHE (0.48) | ACHEACP3ALDH1A1MAPK1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-RE46630-E1 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| WO-2017106340-A1 | ISOTOPIC FLUORINATION AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-9670166-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-20160340319-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-24 | — | — | US | disclosed |
| US-9388140-B2 | Substituted benzimidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-9346794-B1 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9340507-B2 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20160130265-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140057920-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057916-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057926-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2008110314-A1 | FLUORALKYLPHENYLAMIDINES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2008-09-18 | — | — | WO | disclosed |
| EP-1969931-A1 | Fluoroalkyl phenylamidines and their use as fungicides | Bayer CropScience Aktiengesellschaft (DE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1204643-B1 | FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION | DOW AGROSCIENCES LLC (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | SERPINB1, ELANE, MPO | ACHE 452/4885ACP3 2892/4885ALDH1A1 109/4885 |
| US-20140057920-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | ACHE 272/4885ACP3 1747/4885ALDH1A1 299/4885 |
| US-20140057926-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | ACHE 272/4885ACP3 1747/4885ALDH1A1 299/4885 |
| US-20160130265-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | ACHE 272/4885ACP3 1747/4885ALDH1A1 299/4885 |
| US-20160340319-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | ACHE 452/4885ACP3 2892/4885ALDH1A1 109/4885 |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | ACHE 1772/4885ACP3 2172/4885ALDH1A1 1831/4885 |
| US-20140057916-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | ACHE 272/4885ACP3 1747/4885ALDH1A1 299/4885 |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | ACHE 452/4885ACP3 2892/4885ALDH1A1 109/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | ACHE 4527/4885ACP3 2014/4885ALDH1A1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.